Biological Products
AssigneeUCB Pharma S.A.
InventorsRalph Adams, Laura Hancock, Sam Philip Heywood
Life of this patent
Estimating the term…
Abstract
A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab′ fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween.
Claims12
A nucleic acid molecule encoding a divalent antibody fusion protein, comprising:
- (i) an immunoglobulin moiety with a specificity for an antigen of interest,
- wherein the immunoglobulin moiety is a Fab or Fab′ fragment having a heavy chain and a light chain;
- and
- (ii) two single domain antibodies (dAb), a VH dAb and a VL dAb, that together bind to the same human serum albumin,
- wherein the VH dAB comprises complementary determining region (CDR)-H1 having the amino acid sequence set forth in SEQ ID NO:56, CDR-H2 having the amino acid sequence set forth in SEQ ID NO:57, and CDR-H3 having the amino acid sequence set forth in SEQ ID NO:58;
- wherein the VL dAB comprises CDR-L1 having the amino acid sequence set forth in SEQ ID NO:59, CDR-L2 having the amino acid sequence set forth in SEQ ID NO:60, and CDR-L3 having the amino acid sequence set forth in SEQ ID NO:61;—
- wherein (i) the VH dAb is connected directly or via a linker to the C-terminus of the Fab or Fab′ heavy chain and the VL dAb is connected directly or via a linker to the C-terminus of the Fab or Fab′ light chain, or (ii) the VH dAb is connected directly or via a linker to the C-terminus of the Fab or Fab′ light chain and the VL dAb is connected directly or via a linker to the Fab or Fab′ heavy chain;
- and
- wherein the VH dAb and the VL dAb are linked by a disulfide bond between two engineered cysteine residues at positions VH44 and VL100.
Dependencies are inferred from the claim text.